Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 8/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9025375 | 0.89 | ALDH1A1 (0.42) | FFAR2BRD4MEN1LMNAKMT2A | |
| SCHEMBL9026742 | 0.83 | ATM (0.38) | BRD4KMT2ACREBBPAOC3KDM4E | |
| SCHEMBL2593085 | 0.83 | SLC6A3 (0.44) | BRD4LMNACREBBPHPGDALDH1A1 | |
| SCHEMBL8631273 | 0.83 | BRD4 (0.41) | BRD4LMNAALDH1A1 | |
| SCHEMBL8631276 | 0.81 | BRD4 (0.41) | BRD4MEN1KMT2ACREBBP | |
| SCHEMBL8633179 | 0.81 | CYP3A4 (0.40) | BRD4MEN1LMNAKMT2AALDH1A1 | |
| SCHEMBL8683323 | 0.80 | KDM4E (0.43) | MEN1LMNAKMT2AALDH1A1KDM4E | |
| SCHEMBL8633346 | 0.78 | LMNA (0.40) | MEN1LMNAKMT2A | |
| SCHEMBL15615745 | 0.78 | SLC6A2 (0.40) | MEN1LMNAKMT2AALDH1A1KDM4E | |
| SCHEMBL8632721 | 0.74 | ALOX5 (0.33) | KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957086-B2 | Compounds and methods of treating brain disorders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957086-B2 | Compounds and methods of treating brain disorders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-02-17 | — | — | US | disclosed |
| WO-2014013338-A2 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | SGC PHARMA, INC. (CA) | 2014-01-23 | — | — | WO | disclosed |
| US-20130131099-A1 | COMPOUNDS AND METHODS OF TREATING BRAIN DISORDERS | THATCHER GREGORY R J (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131099-A1 | COMPOUNDS AND METHODS OF TREATING BRAIN DISORDERS | THATCHER GREGORY R J (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2011140198-A2 | COMPOUNDS AND METHODS OF TREATING BRAIN DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-11-10 | — | — | WO | disclosed |
| US-5712299-A | TREATMENT OF NEURODEGENERATIVE DISORDERS | ASTRA AKTIEBOLAG (SE) | 1998-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131099-A1 | COMPOUNDS AND METHODS OF TREATING BRAIN DISORDERS | NLN, PYGB, OTC | FFAR2 2626/4885BRD4 4418/4885MEN1 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.